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Abstract
Objective To evaluate the psychometric properties of the
VVSymQ instrument, a new 5-item patient-reported
outcome (PRO) measure for symptoms of varicose veins.
Method The VVSymQ electronic daily diary was
administered to outpatients who received routine treatment
for varicose veins (N = 40). Compliance with diary
administration and item score variability, reliability, con-
struct validity, sensitivity to change, and clinically mean-
ingful change were evaluated.
Results Patients completed[97 % of scheduled diary
assessments (at screening, baseline, and week 8). The
VVSymQ instrument captured patients’ pre-treatment
symptoms (all VVSymQ symptoms were endorsed
by C75 % of patients at baseline), and the change post-
treatment (mean change in score -6.1), with a large
Cohen effect size (1.6). Test–retest reliability was high
(intraclass correlation coefficient 0.96); internal consis-
tency was good (Cronbach’s alpha C0.76; baseline,
week 8). VVSymQ scores were more strongly associated
with PRO scores that reflect symptoms and symptom
impact (the Venous Insufficiency Epidemiological and
Economic Study—Quality of Life/Symptoms [VEINES-
QOL/Sym] instrument and the Chronic Venous Insuffi-
ciency Quality-of-Life Questionnaire [CIVIQ-20]) than
with PRO scores that reflect appearance (the Patient Self-
Assessment of Appearance of Visible Varicose Veins
[PA-V3]) or clinician-reported outcome scores (the Clin-
ical–Etiology–Anatomy–Pathophysiology [CEAP] Classi-
fication of Venous Disorders and Venous Clinical
Severity Score [VCSS]), demonstrating construct validity.
Patients reporting that symptoms were ‘‘moderately’’ or
‘‘much improved’’ on the Patient Global Impression of
Change (PGIC) anchor (i.e.,[97 % of patients) had mean
improvements of -6.3 VVSymQ points, while a
cumulative distribution curve showed that 50 % of
patients improved by C-5.8 points; thus, a score change
of approximately -6 demonstrated a clinically meaning-
ful change in this study. The clinically meaningful change
in the VVSymQ score was greater in patients with a
greater baseline VVSymQ symptom burden, and the
VVSymQ instrument captured clinically meaningful
treatment benefit even in patients with a low baseline
symptom burden.
Conclusion The 5-item VVSymQ instrument is a brief,
psychometrically sound, useful tool for evaluating patient-
reported varicose veins symptoms.
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Key Points for Decision Makers
Until now, there has been no patient-reported
outcomes (PRO) instrument for evaluating
symptoms alone in patients with varicose veins that
has undergone development according to the US
Food and Drug Administration PRO Guidance.
This psychometric evaluation of the 5-item
VVSymQ electronic daily diary in patients who
underwent treatment for varicose veins showed that
the instrument was easy to use by patients, is reliable
and valid, and captured the change in symptoms after
treatment, with a very large effect size.
The VVSymQ instrument is a psychometrically
sound, useful tool for evaluating patient-reported
symptoms of varicose veins. The instrument may be
useful for capturing treatment benefit and monitoring
the symptom experience of patients over time in
clinical research and practice.
1 Background
Varicose veins are extremely common, affecting up to
73 % of women and up to 56 % of men [1]. Varicose veins
and the associated chronic venous insufficiency have a
substantial impact on patient quality of life (QOL) [2, 3]
and are among the most common vascular conditions
requiring specialist treatment [4]. Signs and symptoms of
varicose veins are important to patients [Paty et al. Content
Validity for the VVSymQ Instrument: A New Patient
Reported Outcome Measure for the Assessment of Vari-
cose Veins Symptoms (Patient, manuscript in review,
2016), 5] and are markers of treatment benefit. Treatments
for varicose veins can benefit patients by improving the
appearance of leg veins and by reducing symptoms and
symptom impact on health-related QOL. Since symptoms
(e.g., pain, burning, swelling) are not observable by clini-
cians, they are best measured by querying patients directly,
using patient-reported outcome (PRO) instruments [6].
Various PRO instruments have been used to assess
patients who have varicose veins, including generic PRO
measures (e.g., the SF-36 Health Survey), which do not
address venous-specific symptoms and impacts, and condi-
tion-specific instruments, such as the Aberdeen Varicose
Veins Questionnaire (AVVQ) [7], the Venous Insufficiency
Epidemiological and Economic Study—Quality of Life/
Symptoms (VEINES-QOL/Sym) instrument [8], the Speci-
fic Quality of Life and Outcome Response—Venous Ques-
tionnaire (SQOR-V) [9], and the Chronic Venous
Insufficiency Quality-of-Life Questionnaire (CIVIQ-20)
[10]. Although they are widely used, none of these existing
measures focus solely on varicose vein symptom assessment,
and they have not followed best practices for instrument
development and validation (e.g., see the US Food and Drug
Administration [FDA] PRO Guidance [6]), having been
developed prior to publication of the FDA PRO Guidance.
A new electronic PRO daily symptom diary, the
VVSymQ1 instrument, was developed to assess the key
symptoms of superficial venous incompetence of the great
saphenous vein system that are important and relevant to
patients, including heaviness, achiness, swelling, throbbing,
and itching (Paty et al. Content validity for the VVSymQ
instrument [Patient, manuscript in review, 2016]) [5].
Development and validation of the VVSymQ instrument
followed established instrument development guidelines [6,
11]. Previous work on the VVSymQ instrument established
the content validity of the measure and demonstrated patient
understanding of the instructions, items, and response
options [5]. This article reports results from a psychometric
evaluation of the VVSymQ instrument, using data from a
single-center study of patients with varicose veins.
2 Objectives
The specific objectives of this research were to (1) examine
whether the 5-item VVSymQ instrument appropriately
reflects patients’ experience of varicose vein symptoms;
(2) evaluate the quantitative psychometric properties (item
distributions, reliability, validity, ability to detect change)
of the VVSymQ instrument; (3) identify responder defi-
nitions that can be used to determine if a patient has
experienced a clinically meaningful change on the instru-
ment; and (4) evaluate the administrative feasibility of the
instrument as an electronic daily diary.
3 Methods
3.1 Study Design
The psychometric performance of the VVSymQ instru-
ment was evaluated in a single-center study that was
designed to evaluate its measurement properties. The eval-
uation was conducted in the context of treating patients with
the site’s standard of care for varicose veins. The single-
center site was selected for this study on the basis of its
experience with and access to the targeted sample. The
screening population included all patients available to
1 VVSymQ is a registered trademark of Provensis Ltd., a BTG
International group company.
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participating investigators who had a clinical diagnosis of
great saphenous vein incompetence (varicose veins) and
were scheduled for treatment with ultrasound-guided foam
sclerotherapy. Patients received compensation of up to £150
for their time and travel. Patients came to the clinic on three
occasions (Table 1). At each visit, patients completed three
PRO instrument questionnaires (the Modified VEINES-
QOL/Sym, CIVIQ-20, and Patient Self-Assessment of
Appearance of Visible Varicose Veins [PA-V3]), and clini-
cians completed a clinician-reported outcome (ClinRO)
instrument (the Venous Clinical Severity Score [VCSS]).
Clinicians also completed the Clinical–Etiology–Anatomy–
Pathophysiology (CEAP) Classification of Venous Disor-
ders at visit 1. Data from these measures were used to
evaluate the construct validity of the VVSymQ instrument.
Patients completed the VVSymQ instrument as part of a
larger electronic daily diary (evening report) for approxi-
mately 14 days between visits 1 and 2 (where week 1 of
electronic daily diary use was considered the screening
period and week 2 was considered the baseline period). At
visit 2, patients received treatment for their varicose veins.
Immediately prior to visit 3 (8 weeks after treatment),
patients completed the evening report, using the electronic
daily diary, for approximately 10 days. This was considered
the post-treatment period.
3.2 Patient Population
Adult outpatients (aged C18 years) with physician-diag-
nosed saphenofemoral junction incompetence who were
scheduled to receive treatment in the UK (ultrasound-
guided sodium tetradecyl sulfate foam sclerotherapy) for
great saphenous vein incompetence (varicose veins) in
one leg were eligible to participate in the study. Patients
were required to be symptomatic, with a screening
symptom score of C7 as derived from question 1 on the
Modified VEINES-QOL/Sym instrument. Patients were
excluded from the study if they were generally unable to
complete an electronic daily diary in accordance with the
protocol; had participated in any other investigational
pharmaceutical product or device study within 3 months




3.3.1.1 VVSymQ Instrument The VVSymQ is a 5-item
PRO instrument that measures heaviness, achiness, swel-
ling, throbbing, and itching associated with varicose veins
Table 1 Schedule of study assessments
Action Screening and baseline
visit 1,
day -28








Informed consent, calculation of score derived from question 1 on the
Modified VEINES-QOL/Sym, demographics, inclusion and exclusion
criteria, CEAP assessment, training of patient to use electronic diary
4
Patient self-assessments
Daily diary (daily assessment of varicose vein symptoms and activity
in the electronic diary)
4a 4a
Modified VEINES-QOL/Sym 4 4b 4c
CIVIQ-20 4 4b 4c
PA-V3 4 4b 4c
PGIC in symptoms 4c
Trained health care professional assessment
VCSS 4 4b 4c
Return electronic diary 4
Varicose vein treatment 4
CEAP Clinical–Etiology–Anatomy–Pathophysiology Classification of Venous Disorders, CIVIQ-20 Chronic Venous Disease Quality-of-Life
Questionnaire, PA-V3 Patient Self-Assessment of Appearance of Visible Varicose Veins, PGIC Patient Global Impression of Change,
VCSS Venous Clinical Severity Score, VEINES-QOL/Sym Venous Insufficiency Epidemiological and Economic Study—Quality of Life/
Symptoms
a Patients used the daily diary for at least 14 days immediately prior to visit 1 and for 10 days immediately prior to visit 3, with the last day
being the day before the visit
b Had to have been completed before treatment
c Had to have been completed after post-treatment electronic diary collection
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[5, 11]. All items assess symptom duration and use a
6-point Likert-type response scale ranging from ‘‘none of
the time’’ (score 0 points) to ‘‘all of the time’’ (score
5 points). The VVSymQ instrument yields a daily sum
score that ranges from 0 to 25, with higher scores indi-
cating greater symptom duration. The VVSymQ score is
the average of the daily scores over 7 days.
3.3.1.2 Daily Diary for Varicose Vein Symptoms and
Activity The VVSymQ instrument was administered as
part of a larger electronic questionnaire, the Daily Diary for
Varicose Veins—Symptoms and Activity (hereafter refer-
red to as the ‘‘daily diary’’) (see Fig. 1) [5, 11]. The daily
diary alarmed each evening to remind the patient to com-
plete the items. In addition to the 5-item VVSymQ
instrument, patients completed 15 other items as part of the
evening report (a total of 20 items). This included four
items to assess additional varicose vein symptoms (heating/
burning sensation, tingling sensation, night cramps, and
restless legs) on a 6-point duration-based response scale;
nine items to assess all of the varicose vein symptoms on a
0–10 intensity-based numeric rating scale; and two items to
assess daily activity (overall activity level, time spent sit-
ting or standing without moving around), using a 6-point
response scale.
The following scores were calculated from the elec-
tronic daily diary data:
5-item duration: sum of items 1–5 (range 0–25)
[VVSymQ instrument].
7-item duration: sum of items 1–7 (range 0–35).
9-item duration: sum of items 1–9 (range 0–45).
5-item intensity: sum of items 1–5 (range 0–50).
7-item intensity: sum of items 1–7 (range 0–70).
9-item intensity: sum of items 1–9 (range 0–90).
3.3.1.3 CIVIQ-20 The Chronic Venous Insufficiency
Quality-of-Life Questionnaire (CIVIQ-20) is a 20-item
PRO instrument that assesses symptoms, actions and
activities, and feelings over the past 4 weeks [10]. The
CIVIQ-20 uses a 5-point Likert-type response scale rang-
ing from 0 (no trouble, minimal problem) to 5 (greatest
intensity or trouble). The overall score ranges from 0
to 100, with high scores indicating greater discomfort or
trouble. The CIVIQ-20 was completed by patients at visits
1, 2, and 3, and was used in tests of the construct validity
of the VVSymQ instrument.
3.3.1.4 Modified VEINES-QOL/Sym The Modified
Venous Insufficiency Epidemiological and Economic
Study—Quality of Life/Symptoms (Modified VEINES-
QOL/Sym) is a 26-item PRO instrument that assesses QOL
impact and symptoms in individuals who have varicose
veins [8, 12]. Responses are rated on 2- to 7-point response
scales of intensity, frequency, or agreement. For this study,
the original VEINES-QOL/Sym recall was modified from a
1-month recall period to a 1-week recall period. A 1-week
recall period was used because the authors were concerned
that patients may not be able to reliably recall varicose vein
symptom experience over a month-long period. Recent
research has indicated that a decision regarding recall for
PROs is dependent on the anticipated attributes of a disease
[13], and the FDA PRO Guidance recommends ‘‘items
with short recall periods or items that ask patients to
describe their current or recent state’’ for symptom
reporting [6].
The instrument was completed by patients at visits 1, 2,
and 3. The QOL domain scores range from 0 to 100 (higher
scores indicate better QOL). The VEINES-QOL score was
used in tests of the construct validity of the VVSymQ
instrument.
3.3.1.5 PA-V3 The Patient Self-Assessment of Appear-
ance of Visible Varicose Veins (PA-V3) is a single-item
PRO instrument that assesses the appearance of varicose
veins in each leg separately, using a 5-point Likert-type
response scale ranging from ‘‘not at all noticeable’’ to
‘‘extremely noticeable’’ [14]. Before treatment, the patient
rated the appearance of both legs. After treatment, the
patient assessed only the treated leg. In the analysis of
Fig. 1 Sample screenshot from the electronic Daily Diary for
Varicose Veins—Symptoms and Activity
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measurement properties, the ratings only for the treated leg
were analyzed. The PA-V3 was completed by patients at
visits 1, 2, and 3, and was used in tests of the construct
validity of the VVSymQ instrument.
3.3.1.6 PGIC The Patient Global Impression of Change
(PGIC), a single-item PRO with a 7-point Likert-type
response scale ranging from ‘‘much worse’’ to ‘‘much
improved,’’ was administered to patients at visit 3 to assess
their overall impression of change in varicose vein symp-
toms in the treated leg over time. The PGIC was used in
sensitivity analyses and to establish a responder definition
for the VVSymQ instrument.
3.3.2 Clinician Instruments
3.3.2.1 CEAP Classification of Venous Disorders The
Clinical–Etiology–Anatomy–Pathophysiology (CEAP)
Classification of Venous Disorders is a ClinRO instrument
used to characterize the form and severity of chronic
venous disease. The clinical portion of the CEAP has
seven grades of severity, with higher grades generally
indicating worse severity. Only patients with a CEAP
clinical grade of C2 (varicose veins) through C5 (skin
changes with healed ulceration) were eligible for inclu-
sion in this study. The CEAP was completed by clinicians
during visit 1 to classify varicose vein severity and was
used in tests of the construct validity of the VVSymQ
instrument.
3.3.2.2 VCSS The Venous Clinical Severity Score
(VCSS) is a ClinRO instrument that includes a clinician-
administered, single-item PRO pain assessment and clini-
cian ratings of the patient’s superficial veins, venous
edema, skin pigmentation, inflammation, induration, active
ulcer number, active ulcer duration, active ulcer size, and
use of compression therapy. The VCSS yields an overall
score ranging from 0 to 30, with higher scores representing
greater severity. The VCSS was completed by clinicians at
visits 1, 2, and 3, and was used in tests of the construct
validity of the VVSymQ instrument.
3.4 Procedure
Patients received training to complete the daily diary
(VVSymQ instrument and 15 other items) on a hand-held
electronic device, and they completed the other PRO
measures (the CIVIQ-20, Modified VEINES-QOL/Sym,
PA-V3, and PGIC) on paper. Clinicians completed the
CEAP and VCSS. The schedule of assessments is shown in
Table 1. Paper measures were transcribed onto electronic
case report forms.
3.5 Ethics Statement
The study protocol was approved by the Black Country
Research Ethics Committee (REC), England, and all
patients provided written informed consent prior to par-
ticipating in the study.
3.6 Handling of Data
The screening population included all patients who signed
informed consent, and the study population included all
patients who provided data for at least one post-screening
assessment.
The daily VVSymQ scores provided by the patient
during the week preceding a scheduled study visit were
averaged and used as the representative score for the
patient’s visit. Four completed days (consecutive or non-
consecutive) were necessary to derive a VVSymQ score,
otherwise the data were considered missing for that week.
The 7-day average VVSymQ score (for baseline and for
week 8) was the average of the summed score (including
imputed scores; see below) across 7 days. The same
approach was taken for the other scores based on daily
diary data.
For missing VVSymQ data, if at least 4 but not all
7 days had all of the comprising items scored, missing
items from any given day were imputed on the basis of the
average of the non-missing scores for that item across the
7 days. The electronic daily diary did not allow skipping of
any of the 20 questions.
For missing Modified VEINES-QOL/Sym data, if more
than 50 % of the items on a particular subscale were
missing, the score for that subscale was set to missing,
otherwise the subscale score was calculated as the sum of
the scores of the items present, multiplied by the ratio of
the maximum possible number of all items to the number
of items present.
For the CIVIQ-20, mean imputation methods for miss-
ing items occurred if 50 % or more of the subscale items
were present.
3.7 Analyses
The psychometric performance of the VVSymQ instru-
ment was evaluated using standard analytic procedures and
measurement review criteria developed by the Scientific
Advisory Committee of the Medical Outcomes Trust [15]
and further elaborated by the US FDA [6, 16].
3.7.1 Administrative Feasibility
The administrative feasibility of electronic daily diary data
collection was analyzed in terms of the completeness of the
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data obtained (compliance) based on the actual number of
completed assessments compared with the expected number
of assessments. Three periods were identified for analysis of
the electronic daily diary data: screening (days -14 to -8);
baseline (days -7 to -1, with day 0 being the treatment
day); and post-treatment (the seven calendar days preceding
visit 3, or week 8). For each patient, an individual com-
pliance rate (percentage) was calculated (number of com-
pleted diary entries relative to total number of all scheduled
entries in the particular reporting period), and then the mean
percentage across all patients in that reporting period was
calculated to obtain the compliance rate.
3.7.2 Scoring Evaluation
To determine if a 5-item duration-based VVSymQ score
appropriately reflects the patients’ experience of symp-
toms, given that nine symptoms from the broader daily
diary were assessed on both duration and intensity response
scales, Pearson r correlations were examined between the
VVSymQ score and scores for the 7- and 9-item duration-
based symptom instrument versions, and also between the
VVSymQ score and scores for the 5-, 7-, and 9-item
intensity-based symptom instrument versions at baseline,
and for the changes in scores from baseline to week 8.
3.7.3 Item Distribution and Descriptive Statistics
VVSymQ item scores at baseline and post-treatment
(week 8) were assessed through an examination of fre-
quency and descriptive statistics. Item floor or ceiling
effects were concluded for baseline data if[50 % of
patients reported no symptom duration (‘‘none of the
time’’) or the greatest symptom duration (‘‘all of the
time’’). Descriptive statistics (i.e., the mean, standard
deviation [SD], median, minimum, and maximum) were
calculated for baseline and week 8 VVSymQ scores, and
for changes in VVSymQ scores at week 8.
3.7.4 Reliability
The extent of agreement between scores obtained on dif-
ferent days and during different periods was evaluated in
terms of distributions of difference scores between
assessments for different days, and using both nonpara-
metric measures (kappa values) and parametric measures
(intraclass correlation coefficients [ICCs]). ICCs were used
to assess whether the VVSymQ instrument yielded
reproducible scores during a stable period (i.e., from
screening to baseline, when only a minimal change or no
change in the condition was expected). Values of 0.75 or
higher for ICCs are generally considered satisfactory (see,
for example, Portney and Watkins [17], Fleiss [18], and
Gwaltney et al. [19]). Internal consistency of the data was
evaluated using Cronbach’s alpha; values C0.7 are con-
sidered good to excellent ([0.9).
3.7.5 Construct Validity
Construct validity (how well an instrument measures the
constructs it was designed to measure) was evaluated
through an examination of Pearson r correlation coeffi-
cients for the relationship between VVSymQ scores and
scores on the VEINES-QOL, CIVIQ-20, PA-V3, CEAP,
and VCSS (for baseline and week 8, and for changes from
baseline to week 8). Pearson r correlation coeffi-
cients C0.70 indicate a strong relationship between vari-
ables [20]. The VVSymQ scores were expected to be
more strongly associated with the PRO instrument scores
that assess symptoms or symptom impact (the VEINES-
QOL and CIVIQ-20) than with the PRO instrument score
that reflects appearance (the PA-V3) or the ClinRO
instrument scores (the CEAP and VCSS). Higher correla-
tion coefficients support convergence between measures
(i.e., that they are measuring similar constructs), and lower
correlation coefficients indicate divergence between mea-
sures (i.e., that they are measuring dissimilar constructs).
3.7.6 Ability to Detect Change
Central to understanding the performance of the
VVSymQ instrument is the concept that changes in the
clinical condition are reflected in instrument scores. The
mean changes in VVSymQ score from baseline to week 8
was evaluated with Cohen effect size statistics (i.e., the
change in the mean value from baseline to week 8,
expressed as a proportion of the SD of the baseline [pre-
treatment] score). Effect size thresholds of 0.2, 0.5, and 0.8
or greater are interpreted as small, moderate, and large
effect sizes, respectively [21].
3.7.7 Clinically Meaningful Change
In the PRO context, clinically meaningful change reflects
the point at which a change in a score can be interpreted as
clinically important from the perspective of the patient, and
is used to understand test scores beyond what is provided
for by ‘‘statistically significant’’ results. An anchor-based
approach was used to assess clinically meaningful changes
in VVSymQ scores [22]. Anchor-based methods use an
external criterion to categorize patients into groups, each
reflecting predetermined change groupings (e.g., no
change, large positive change, large negative change).
VVSymQ scores (means and SDs) were computed for
each level of change reported on the PGIC items. The
minimal important difference (MID) is the smallest
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difference or change in score (from baseline to week 8)
that is important to the patient (e.g., those reporting
‘‘a little improved’’ on the PGIC).
A cumulative distribution curve was also produced for the
VVSymQ instrument. Cumulative distribution curves dis-
play information on what type of responses contributed to the
mean group response and provide more useful data than a
simple point estimate of the difference between group mean
changes [16], allowing the percentage of responders in the
group to be determined at all possible response thresholds
(e.g., 25 % improvement, 3-point improvement).
4 Results
Forty-two patients were screened for the study; two
patients scored\7 on question 1 of the Modified VEINES-
QOL/Sym instrument and, thus, were not enrolled. Forty
patients were enrolled, and all of them completed the study.
No patients withdrew from the study. Demographic char-
acteristics are shown in Table 2.
4.1 Administrative Feasibility of Electronic Daily
Diary
Compliance with completion of the electronic daily diary
was extremely high, with over 97 % of scheduled entries
being completed for each of the three assessment periods
(screening, baseline, and post-treatment), and with only
6 of 274 entry days missed.
4.2 Scoring Evaluation
The correlations between the 5-item duration-based
VVSymQ score and the other alternative scores (the 7-
and 9-item symptom duration scores and the 5-, 7-, and 9-
item intensity scores) ranged from 0.91 to 0.98 (at base-
line). Also, correlations of change from baseline to week 8
for the 5-item duration-based VVSymQ score and other
alternative scores ranged from 0.89 to 0.98. This high level
of concordance, in which all configurations of scores were
highly redundant, suggests that the instruments are
assessing the same underlying construct of symptom
experience; thus, the shortest version of the instrument (the
5-item duration-based VVSymQ instrument) was further
evaluated in this study for psychometric performance.
4.3 Item Distribution and Descriptive Statistics
All five VVSymQ symptoms were endorsed by at least
75 % of patients in the screening and baseline periods (i.e.,
days -14 to -8 and days -7 to -1, respectively).
VVSymQ items were slightly positively skewed (i.e.,
toward lower scores), and no ceiling or floor effects were
observed at baseline (Table 3). Table 4 presents descrip-
tive statistics for the VVSymQ scores at baseline and at
week 8, and the changes in VVSymQ scores at week 8.




Mean (SD) 49.7 (13.9)













Mean (SD) 6.3 (2.42)
Median (range) 5.0 (3–12)
CEAP Clinical–Etiology–Anatomy–Pathophysiology Classification
of Venous Disorders, SD standard deviation, VCSS Venous Clinical
Severity Score
a n = 39
Table 3 Distribution of 5-item VVSymQ (7-day average) scores at
baseline and post-treatment (week 8)
Parameter Symptom score, % of patients reportinga,b
0 1 2 3 4 5
Baseline
Heaviness 26.9 27.6 21.5 14.5 8.7 0.7
Achiness 11.3 33.1 24.7 18.9 10.2 1.8
Swelling 37.1 18.5 18.5 10.5 11.3 4.0
Throbbing 34.5 28.4 19.6 13.1 4.0 0.4
Itching 29.8 24.4 28.7 10.5 2.9 3.6
Post-treatment (week 8)
Heaviness 77.3 21.2 1.5 0.0 0.0 0.0
Achiness 64.1 29.3 6.2 0.4 0.0 0.0
Swelling 69.6 21.2 7.0 1.5 0.7 0.0
Throbbing 86.8 10.6 2.6 0.0 0.0 0.0
Itching 78.4 14.3 3.3 2.9 1.1 0.0
a Score of 0 = none of the time; score of 5 = all of the time
b The percentages for each symptom score are based on the total
number of recorded responses (excluding imputations) during the last
7 calendar days (e.g., days -7 to - 1) of each period; each patient
contributed as many as 7 observations per diary period
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Patients’ mean VVSymQ item scores for each symptom
at baseline ranged from 1.3 to 1.9 (on a 0–5 scale), indi-
cating that they generally experienced each of the
symptoms ‘‘a little of the time’’ to ‘‘some of the time’’ each
day. At the end of the post-treatment period (week 8),
patients’ mean scores on individual symptoms were
reduced to 0.4 or below, indicating that patients were
experiencing symptoms between ‘‘none of the time’’ and
‘‘a little of the time’’ each day. The results demonstrate that
the duration of symptom reporting reduced with treatment.
4.4 Reliability
The agreement between scores on items from one day to
the next was very high for the VVSymQ instrument
(Table 5). The scale range for the VVSymQ score is
0–25, and the range of mean scores was approximately
6 units. When the mean scores for days -7 to - 2 (during
the baseline period) were compared with the mean score
for day -1, the modal deviation was 1 scale unit in all
cases. There was little or no tendency for scores to differ
more markedly, as assessed by absolute agreement, kappa
Table 4 Descriptive statistics for 5-item VVSymQ scores (7-day
average) of the study population (N = 40) at baseline and post-
treatment (week 8), and change at week 8
Score, mean (SD)
Baseline Week 8 Change from baseline
Symptom
Heaviness 1.6 (1.21) 0.3 (0.37) -1.3 (1.15)
Achiness 1.9 (1.11) 0.4 (0.45) -1.5 (1.07)
Swelling 1.5 (1.47) 0.4 (0.67) -1.1 (1.15)
Throbbing 1.3 (0.99) 0.2 (0.32) -1.1 (0.90)
Itching 1.4 (1.16) 0.4 (0.69) -1.1 (0.93)
Total score 7.7 (4.38) 1.6 (1.86) -6.1 (3.70)
SD standard deviation
Table 5 Agreement of VVSymQ scores (0–25) of the study population (N = 40) during screening and at baseline
Score Patients, n (%)




Comparison with day -1
Exact match 2 (5.0) 5 (12.5) 11 (27.5) 11 (27.5) 6 (15.0) 7 (17.5) 17 (42.5) 5 (12.5)
Differ by[0 to B1 14 (35.0) 11 (27.5) 12 (30.0) 11 (27.5) 10 (25.0) 15 (37.5) 11 (27.5) 11 (27.5)
Differ by 1 to B2 13 (32.5) 8 (20.0) 5 (12.5) 5 (12.5) 10 (25.0) 6 (15.0) 6 (15.0) 14 (35.0)
Differ by[2 to B3 4 (10.0) 4 (10.0) 6 (15.0) 4 (10.0) 7 (17.5) 2 (5.0) 4 (10.0) 6 (15.0)
Differ by[3 to B4 2 (5.0) 8 (20.0) 4 (10.0) 2 (5.0) 3 (7.5) 5 (12.5) 3 (7.5)
Differ by[4 to B5 2 (5.0) 3 (7.5) 3 (7.5) 2 (5.0) 2 (5.0)
Differ by[5 3 (7.5) 1 (2.5) 2 (5.0) 4 (10.0) 4 (10.0) 3 (7.5) 1 (2.5)
Simple kappa -0.013 0.073 0.216 0.227 0.094 0.122 0.385 0.073
Weighted kappa 0.559 0.574 0.663 0.592 0.560 0.585 0.773 0.612
Intraclass correlation
coefficient
0.767 0.826 0.859 0.775 0.797 0.785 0.919 0.867
Comparison with screening days (-7 to -1)
Exact match 13 (32.5) 13 (32.5) 12 (30.0) 14 (35.0) 18 (45.0) 13 (32.5) 17 (42.5) 15 (37.5)
Differ by[0 to B1 13 (32.5) 10 (25.0) 12 (30.0) 15 (37.5) 9 (22.5) 17 (42.5) 11 (27.5) 12 (30.0)
Differ by[1 to B2 3 (7.5) 7 (17.5) 10 (25.0) 2 (5.0) 5 (12.5) 4 (10.0) 6 (15.0) 11 (27.5)
Differ by[2 to B3 4 (10.0) 7 (17.5) 4 (10.0) 4 (10.0) 4 (10.0) 1 (2.5) 4 (10.0) 2 (5.0)
Differ by[3 to B4 5 (12.5) 2 (5.0) 2 (5.0) 1 (2.5) 3 (7.5) 2 (5.0)
Differ by[4 to B5 1 (2.5) 3 (7.5) 1 (2.5) 2 (5.0)
Differ by[5 2 (5.0) 1 (2.5) 3 (7.5)
Simple kappa 0.280 0.276 0.248 0.299 0.403 0.271 0.385 0.316
Weighted kappa 0.673 0.729 0.741 0.705 0.757 0.714 0.773 0.788
Intraclass correlation
coefficient
0.843 0.923 0.923 0.872 0.933 0.890 0.919 0.960
When reproducibility is evaluated, scores are expected to remain stable for the same respondents over a period of time when minimal or no
change in the condition is expected. Table 5 presents the VVSymQ score agreement during this study’s screening-to-baseline 7-day period. The
frequency of exact matches and differences in score are presented in relation to patients’ scores for day -1. For example, two patients scored
exactly the same on the VVSymQ on days -7 and -1, while three patients had a score difference of[5 on the VVSymQ on days -7 and -1
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values, or ICCs, when separated by greater time intervals
(e.g., there was little or no difference between the day -
2/-1 comparison and the day -7/-1 comparison). Similar
results were observed when each of the daily scores was
compared with the mean score for days 1–7. Scores for
days -14 to -8 showed slightly less agreement with day -
1 scores than did scores for days -7 to -1. The ICC of the
comparison between the mean VVSymQ score at baseline
(days -14 to -8) and screening (days -7 to -1) was 0.96.
A similar pattern was observed in the kappa values (non-
parametric assessment of agreement). The Cronbach’s
alpha values for the VVSymQ instrument at baseline and
week 8 were 0.78 and 0.76, respectively.
4.5 Construct Validity
Table 6 shows the results from correlation analyses used in
the examination of construct validity. VVSymQ scores
showed strong correlations with the Modified VEINES-
QOL scores at baseline (r = -0.73) and week 8 (r = -
0.75), and for change from baseline to week 8 (r = -
0.67). The correlations were negative because higher
VEINES-QOL scores indicate better health, while higher
VVSymQ scores indicate worse symptoms. The CIVIQ-
20 showed moderate correlations with the VVSymQ
instrument at baseline (r = 0.52) and week 8 (r = 0.59),
and for changes from baseline to week 8 (r = 0.48). The
CIVIQ-20 subscales with the strongest relationship to
symptoms were Pain and Psychological (with r values
ranging from 0.54 to 0.64 for Pain and from 0.34 to 0.60
for Psychological for baseline, week 8, and changes at
week 8) (Table 6). A weaker correlation was also observed
between the VVSymQ score and the PA-V3 appearance
score at baseline (r = 0.32).
No correlation was observed between the VVSymQ
score and the CEAP grade at baseline (r = -0.05). A
moderate correlation was found between the VVSymQ
score and VCSS at week 8 (r = 0.46) but not at baseline or
for score changes from baseline to week 8.
4.6 Ability to Detect Change
A large reduction in the VVSymQ mean score (-6.1,
indicating symptom improvement) was observed between
baseline and week 8 (Table 4), resulting in a very large
effect size of 1.6.
4.7 Clinically Meaningful Change
Of the 40 patients who completed the PGIC, 35 (87.5 %)
reported that their symptoms were ‘‘much improved,’’ four
(10 %) reported that their symptoms were ‘‘moderately
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‘‘a little improved’’ (Table 7). No patient reported an
unchanged or worsened condition. Typically, the threshold
for determining clinically meaningful change is based on
the change in the score associated with patients who
reported that their symptoms were ‘‘moderately improved.’’
However, in this study, there were so few patients in the
‘‘moderately improved’’ group that the threshold was
determined by the mean improvement of patients who were
either ‘‘moderately improved’’ or ‘‘much improved’’. The
group of patients who reported on the PGIC that their
symptoms were ‘‘moderately improved’’ or ‘‘much
improved’’ had a mean improvement of -6.3 points on the
VVSymQ instrument, indicating that the upper limit of the
clinically meaningful threshold for change in VVSymQ
scores was approximately -6.3 for treatment responders
(Table 7). Improvements on the VVSymQ instrument
varied according to the baseline symptom burden: patients
with baseline VVSymQ scores B7, 7–10, and[10 who
reported that their symptoms were ‘‘moderately improved’’
or ‘‘much improved’’ on the PGIC after treatment had mean
improvements in VVSymQ scores of -3.8, -7.5, and -
11.1, respectively (Table 8).
In order to provide further information for a responder
definition, a cumulative distribution was developed for the
VVSymQ instrument and is shown in Fig. 2. The cumu-
lative distribution curve shows that 50 % of patients had an
improvement of at least -5.8 points on the VVSymQ
instrument.
Table 7 Mean changes in
VVSymQ scores (from
baseline to week 8) according to
Patient Global Impression of
Change (PGIC) symptom scores
at week 8
PGIC symptom VVSymQ score changea
N Mean (SD) Median (range)
Much or moderately improved 39 -6.3 (3.63) -5.9 (-15.2 to -0.7)
Much improved 35 -6.1 (3.69) -5.6 (-15.2 to -0.7)
Moderately improved 4 -7.6 (3.17) -7.8 (-10.7 to -4.0)
Less than moderately improved 1 -0.3 (NA) -0.3 (-0.3 to -0.3)
A little improved 1 -0.3 (NA) -0.3 (-0.3 to -0.3)
No change 0 NA NA
A little worse 0 NA NA
Moderately worse 0 NA NA
Much worse 0 NA NA
NA not applicable, SD standard deviation
a Change from baseline to week 8 (7-day summary of VVSymQ score)
Table 8 Mean changes in VVSymQ scores (from baseline to
week 8) of patients who reported ‘‘moderately improved’’ or ‘‘much
improved’’ Patient Global Impression of Change (PGIC) symptom
scores at week 8, according to baseline VVSymQ scores
Baseline VVSymQ score VVSymQ score changea
N Mean (SD)
B7 22 -3.84 (1.60)
[7 to 10 8 -7.45 (1.06)
[10 9 -11.12 (3.29)
SD standard deviation



























-20 -18 -16 -14 -12 -10 -8 -6 -4 -2 0 2
Fig. 2 Cumulative percentage
of patients at week 8 with
changes from baseline in 7-day
average VVSymQ scores
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5 Discussion
Varicose veins are common and significantly impact
patients’ daily lives. This study examined the psychometric
characteristics of a new PRO instrument for varicose vein
symptoms, which was developed to address the most rel-
evant varicose vein patient experiences and the limitations
of existing PRO and ClinRO instruments. The results from
this study demonstrate the sound psychometric perfor-
mance of the VVSymQ instrument.
The high level of patient compliance with use of the
electronic daily diary (including the VVSymQ instru-
ment) indicated that it is easy to use and is not burdensome
to complete. Though no universally accepted ‘‘gold stan-
dard’’ for compliance exists, rates C85 to 90 % can be
interpreted as strong for clinical trials [17, 18]. In this
context, compliance with the daily diary was observed to
be excellent and supports an electronic diary approach to
measuring symptoms of varicose veins. The results clearly
demonstrate the feasibility of utilizing electronic diaries in
this patient population.
Scores were highly redundant for duration and intensity
instrument versions of varying length; thus, psychometric
properties of the shortest version, the 5-item duration-based
VVSymQ instrument, were evaluated further. The
VVSymQ instrument demonstrated excellent test–retest
reliability and good internal consistency reliability, and it
related to criterion measures as expected. The VVSymQ
instrument was found to be associated, but not redundant,
with other PRO measures. Converging scores were
observed for the VEINES-QOL, CIVIQ-20, and
VVSymQ instruments. The levels of the correlations
between the VVSymQ and VEINES-QOL/Sym instru-
ments showed that higher levels of symptoms are related to
lower levels of vein disease QOL as measured by symptom
complaints and the impact of those symptoms on patients
(i.e., the areas comprising the VEINES-QOL score). Of the
CIVIQ-20 subscales, the Pain and Psychological subscale
scores showed the strongest relationship to the VVSymQ
score. This is not surprising, given that the Pain items
would be expected to be related to symptoms and the
Psychological items ask about the immediate impact of the
condition (e.g., how patients feel about themselves). The
modest significant relationship observed between the
VVSymQ and PA-V3 instruments is not unexpected,
given that the same venous condition is causing both
symptoms and appearance concerns.
The results suggest that there is no clear relationship
between patients’ self-reports of varicose vein symptoms
(the VVSymQ instrument) and ClinRO measures.
Because patients and physicians do not necessarily agree
about the impact of a condition, high correlations were not
anticipated, but r values[0.3 are often found between the
scores for ClinRO and PRO measures in other conditions
(see, for example, Hinchcliff et al. [23] and Mazari et al.
[24]). The ClinRO instruments themselves were correlated
as expected at baseline, indicating that these measures are
reasonably reliable. However, no correlation was found
between the VVSymQ score and CEAP clinical grade. No
correlation was found between the VVSymQ score and
VCSS at baseline and the change scores (from baseline to
week 8); however, a moderate correlation was observed
between the VVSymQ score and VCSS at week 8. These
findings may be attributed to the restricted range in the
scores at baseline (due to inclusion criteria requiring
patients to have a screening symptom score C7 as derived
from question 1 on the Modified VEINES-QOL/Sym
instrument), which can attenuate the correlation between
scales and underestimate the actual true correlation.
Additionally, the PRO and ClinRO measures may be
assessing uniquely different concepts associated with
varicose veins. For instance, the low to moderate correla-
tions observed between the VVSymQ score and VCSS
suggest that the VCSS may characterize disease severity,
yet may not predict patient symptom response [11].
The VVSymQ instrument appears sensitive to changes
in the clinical condition over time. Large reductions were
observed in VVSymQ scores from baseline to week 8,
resulting in a very large effect size of 1.6 [21].
The sample size and diversity may have limited the
findings of this study. This study poses a challenge in
interpreting the definition of a responder based upon the
PGIC anchor. The traditional approach is to compare the
sizes of changes in the outcome measures between patients
showing no improvement, minimal improvement, etc.
However, no patients in this study reported less than
minimal improvement, and only one patient reported
minimal improvement. Thus, the number of patients at the
lower end of the scale was too small to give useful infor-
mation for the separate categories. The mean change in the
7-day average electronic daily diary VVSymQ score of
6.3 noted for all patients who reported ‘‘moderately
improved’’ or ‘‘much improved’’ symptoms on the PGIC
can, therefore, be considered an upper bound for determi-
nation of a criterion for the definition of a responder.
Results from larger studies will allow a more precise
estimate to be obtained.
The findings from the PGIC anchor also suggest that the
threshold for a clinically meaningful change in the
VVSymQ score is higher in patients who had a greater
baseline VVSymQ symptom burden, and that the
VVSymQ instrument can capture a clinically meaningful
treatment benefit even in patients who report a relatively
small baseline symptom burden.
346 D.D.I. Wright et al.
6 Conclusion
The 5-item VVSymQ instrument demonstrated favorable
psychometric properties and is a brief, useful assessment
for measuring patient-reported symptoms of varicose veins.
Understanding the patient’s perspective on their varicose
vein symptoms can allow for a more informed assessment
of treatment efficacy. The VVSymQ instrument assesses
symptoms that are related to the underlying pathophysiol-
ogy of varicose veins and that are important to patients.
This PRO measure may be useful as an efficacy endpoint
alongside other measures of disease severity in future
clinical trials testing new treatments for varicose veins.
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